Figure 8

Pharmacological specificity of cannabinoid-mediated protection against paclitaxel-induced mechanical allodynia following drug removal. a. WIN55,212-2 (0.5 mg/kg/day s.c.)-mediated anti-allodynia following drug removal was dominated by CB₁ receptor activation. b. The protective effects of AM1710 were blocked by AM630 (3 mg/kg/day s.c.) but not AM251 (3 mg/kg/day s.c.)). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Cremophor-Vehicle, ^# P < 0.05, ^## P < 0.01, ^### P < 0.001 vs. Taxol-Vehicle, ^x P < 0.05, ^xx P < 0.01, ^xxx P < 0.001 Taxol-Agonist and Taxol-Agonist + AM251 (3) vs. Taxol-Vehicle, ^⟂ P < 0.05, ^⟂⟂ P < 0.01, ^⟂⟂⟂ P < 0.001 vs. Taxol-Agonist, Taxol-Agonist + AM251 (3) and Cremophor-Vehicle, ^α P < 0.05 Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle, ^β P < 0.05, ^ββ P < 0.01, ^βββ P < 0.001 Taxol-Agonist, Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle, ^ϕϕ P < 0.01 Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630 (3) vs. Taxol-Agonist and Cremophor-Vehicle, ⁺ P < 0.05, ⁺⁺ P < 0.01 vs. Taxol-Agonist, ^tt P < 0.01 Taxol-Agonist + AM251 (3) and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle. Doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey post-hoc tests). N = 6–8 per group.